Gastric Cancer in the Era of Precision Medicine
| Autor: | Stephen J. Meltzer, Xi Liu |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Biomarker identification Preclinical Models MSI microsatellite unstable/instability MSS/EMT microsatellite stable with epithelial-to-mesenchymal transition features MSI-H high microsatellite instability Review Biology Bioinformatics Genome Molecular Classification 03 medical and health sciences Cancer Genomics GTPase guanosine triphosphatase Genetic Evolution miRNA microRNA medicine CIN chromosomally unstable/chromosomal instability LOH loss of heterozygosity TGF transforming growth factor Cancer death EBV Epstein-Barr virus Hepatology business.industry GAPPS gastric adenocarcinoma and proximal polyposis of the stomach Gastroenterology Cancer Precision medicine medicine.disease HDGC hereditary diffuse gastric cancer PDX patient-derived tumor xenografts NGS next-generation sequencing Gastric Cancer hPSC human pluripotent stem cell 030104 developmental biology CIMP CpG island methylator phenotype GC gastric cancer TCGA The Cancer Genome Atlas lncRNA long noncoding RNA Personalized medicine business EBV - Epstein-Barr virus |
| Zdroj: | Cellular and Molecular Gastroenterology and Hepatology |
| ISSN: | 2352-345X |
| DOI: | 10.1016/j.jcmgh.2017.02.003 |
| Popis: | Gastric cancer (GC) remains the third most common cause of cancer death worldwide, with limited therapeutic strategies available. With the advent of next-generation sequencing and new preclinical model technologies, our understanding of its pathogenesis and molecular alterations continues to be revolutionized. Recently, the genomic landscape of GC has been delineated. Molecular characterization and novel therapeutic targets of each molecular subtype have been identified. At the same time, patient-derived tumor xenografts and organoids now comprise effective tools for genetic evolution studies, biomarker identification, drug screening, and preclinical evaluation of personalized medicine strategies for GC patients. These advances are making it feasible to integrate clinical, genome-based and phenotype-based diagnostic and therapeutic methods and apply them to individual GC patients in the era of precision medicine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|